Formulary
Eptifibatide: Indications, Dosing, Side Effects and Interactions
Eptifibatide clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Eptifibatide: Indications, Dosing, Side Effects and Interactions
Eptifibatide clinical drug profile including indications, dosing, side effects, cautions and interactions.
Cautions
Discontinue if emergency cardiac surgery necessary; discontinue if intra-aortic balloon pump necessary; discontinue if thrombolytic therapy necessary; risk of bleeding-discontinue immediately if uncontrolled serious bleeding
Contraindications
Abnormal bleeding within 30 days; haemorrhagic diathesis; history of haemorrhagic stroke; increased INR; increased prothrombin time; intracranial disease; major surgery or severe trauma within 6 weeks; severe hypertension; stroke within last 30 days; thrombocytopenia
Side effects
Common or very common Arrhythmias; atrioventricular block; cardiac arrest; congestive heart failure; haemorrhage; hypotension; intracranial haemorrhage; procedural complications; shock Uncommon Cerebral ischaemia; thrombocytopenia Rare or very rare Rash
Interactions
**Other interactions (6):**
- Bivalirudin, low molecular weight heparin, fondaparinux, and GP IIb/IIIa inhibitors In clinical studies, cangrelor has been co-administered with bivalirudin, low molecular weight heparin,...
- Interaction studies have been conducted with platelet inhibitors, including acetylsalicylic acid, ticlopidine, clopidogrel, abciximab, eptifibatide, or tirofiban.
- Drugs which should be avoided if possible The following examples should be avoided, or administered with caution with increased clinical and laboratory monitoring: - Clopidogrel - NSAIDs (including...
- Potential additive effect with platelet aggregation inhibitors: Because of the increased risk of bleeding, the concomitant administration of a platelet aggregation inhibitor (such as clopidogrel,...
- Drugs which should be avoided if possible The following examples should be avoided, or administered with caution with increased clinical and laboratory monitoring: Clopidogrel NSAIDs (including...
- Anticoagulants, platelet inhibitors, etc: Increased risk of bleeding with oral anticoagulants, epoprostenol, clopidogrel, ticlopidine, streptokinase, dipyridamole, dextran solutions, abciximab,...
Pregnancy
Manufacturer advises use only if potential benefit outweighs risk-no information available.
Breast feeding
Manufacturer advises avoid-no information available.
Hepatic impairment
Manufacturer advises caution; avoid in significant impairment (increased risk of bleeding complications, limited information available).
Renal impairment
Avoid if creatinine clearance less than 30 mL/minute. M Dose adjustments Initially 180 micrograms/kg, then reduce infusion to 1 microgram/kg/minute if creatinine clearance 30-50 mL/minute (increased risk of bleeding; limited information available). M See Prescribing in renal impairment .
Medicinal forms
Solution,Solution
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Eptifibatide in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

